Celgene's most recent trend suggests a bullish bias. One trading opportunity on Celgene is a Bull Put Spread using a strike $129.00 short put and a strike $124.00 long put offers a potential 15.74% return on risk over the next 22 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $129.00 by expiration. The full premium credit of $0.68 would be kept by the premium seller. The risk of $4.32 would be incurred if the stock dropped below the $124.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Celgene is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Celgene is bullish.
The RSI indicator is above 80 which suggests that the stock is in overbought territory.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Celgene
Major Biotech Short Interest Surges
Tue, 27 Jun 2017 12:50:11 +0000
The June 15 short interest data have been compared with the previous report, and short interest in most of the selected biotech stocks increased.
Biotech Stock With 497% Growth, Positive Trial Results Nears Buy Zone
Mon, 26 Jun 2017 20:17:13 +0000
With biotech stocks like Celgene, Bluebird Bio and Regeneron on the move, cancer treatment developer Exelixis may be poised to pop into a new buy zone.
Seattle Genetics: A Disappointing Study…Or Was It?
Mon, 26 Jun 2017 18:52:00 +0000
Shares of Seattle Genetics (SGEN) are moving lower today, falling more than 9% after the drug maker’s experimental lymphoma drug failed to impress. The data from the late-stage study testing Adcetris, co-developed with Japan's Takeda Pharmaceutical, helped blood cancer patients live longer without worsening their conditions, meeting its endpoint. Altogether, lots of uncertainty whether these data could support a robust commercial adoption.
Agio Pharma Sinks on Midstage Trial
Mon, 26 Jun 2017 15:05:35 +0000
Agio Pharmaceuticals saw its shares sink on Monday after the firm announced results from its midstage trial for the treatment of relapsed or refractory acute myeloid leukemia.
Corcept Therapeutics Incorporated in 3 Charts
Mon, 26 Jun 2017 12:43:00 +0000
Corcept has been one of the best-performing drug stocks this year. These charts show why the good times could continue.
Related Posts
Also on Market Tamer…
Follow Us on Facebook